Where a non-hormonal supplement can fit
Hot flashes and night sweats can interrupt sleep, affect working days and persist well beyond the final menstrual period. Up to 80% of women experience vasomotor symptoms during the menopausal transition, although frequency and severity vary considerably. (Flanagan, 2026)
For international distributors, this creates a substantial need for menopause care that accommodates different clinical circumstances and treatment preferences.
The same years often bring a quieter change. Body fat moves toward the abdomen, lipids shift in an unfavorable direction and cardiovascular risk starts to climb. In some women the two problems arrive together, and that overlap is where a non-hormonal supplement with its own clinical data can have a defined role.
Non-hormonal menopause support belongs within that discussion. Its commercial value depends on how accurately a portfolio addresses the need: which symptoms a product targets, what evidence supports it and how healthcare professionals can explain its role. A large patient population alone offers limited guidance for product selection.
Why vasomotor symptoms create a sustained need
Vasomotor symptoms are episodes of hot flashes and night sweats associated with changes in temperature regulation during menopause. Declining estrogen affects the brain pathways involved in thermoregulation, making heat dissipation responses easier to trigger. The resulting episodes can be brief, yet their repeated effects on daily life are often substantial. (Khan et al., 2023)
Severity requires careful interpretation. A multinational survey of postmenopausal women aged 40–65 reported moderate-to-severe symptoms in 40% of respondents in Europe, 34% in the United States and 16% in Japan. (Nappi et al., 2021)
These differences give distributors a reason to examine local care patterns before importing a positioning strategy.
Duration matters just as much. A review published in 2024 describes an average symptom duration of approximately seven years, with persistence beyond a decade in some women. Duration varies considerably and depends on the population studied and symptom definition. (Koysombat et al., 2024)
For menopause care, this makes continuing follow-up and reassessment of treatment needs relevant.
For a distributor, this suggests a category requiring follow-up and realistic expectations. Symptoms may change over time, and women may reassess their treatment with a clinician. Patient education should explain when to review persistent symptoms and how to judge whether an intervention is helping.
What changes in metabolism after menopause
The fall in estrogen also changes how the body stores fat and handles lipids. Longitudinal studies that followed women through the transition have documented more visceral fat, adverse changes in lipids and lipoproteins and a decline in measures of vascular health. A scientific statement from the American Heart Association describes the transition as a time of accelerating cardiovascular risk and a window for early prevention. (El Khoudary et al., 2020)
Metabolic syndrome, the combination of insulin resistance, abdominal obesity, dyslipidemia and raised blood pressure, becomes more common after menopause and affects 31–55% of postmenopausal women. (Janssen et al., 2008)
For a portfolio, the practical point is simple. Many of the women who seek help for hot flashes are the same women whose metabolic profile is starting to change. A product studied in that combined situation answers a narrower and more useful clinical question than a product studied for symptoms alone.
How the WHI changed treatment decisions
The Women’s Health Initiative findings announced in 2002 changed prescribing and public attitudes toward menopausal hormone therapy. An NHANES analysis published in 2024 found that hormone therapy use among US postmenopausal women declined from 26.9% in 1999–2000 to 4.7% in 2017–March 2020. (Yang and Toriola, 2024)
The study documents a trend in use over time; it does not establish how many women subsequently bought supplements.
That history helps explain interest in non-hormonal options, alongside contraindications and personal preferences. It also calls for balanced communication. Hormone therapy remains the most effective treatment for vasomotor symptoms.
The North American Menopause Society (now The Menopause Society) in its 2022 statement describes a favorable benefit-risk ratio for appropriately selected women younger than 60 or within ten years of menopause onset, without contraindications. (The North American Menopause Society, 2022)
A credible menopause portfolio therefore gives healthcare professionals clear choices. A 2025 observational analysis of prescribing in Wales illustrates how route of administration, time period and socioeconomic circumstances matter to hormone therapy uptake and continuation. (Andrews et al., 2025)
Historical trends need interpretation within the local context. Communication built on general fear of hormones risks misinforming women and weakening professional trust.
Where supplements stand in the evidence
Phytoestrogens are plant compounds capable of interacting with estrogen receptors. A supplement containing them can be marketed without pharmaceutical hormones while still having estrogen-related biological activity. Buyers should understand that distinction when assessing suitability and communication.
The Menopause Society’s 2023 evidence review did not recommend supplements, herbal remedies or soy extracts for treating vasomotor symptoms. It identified evidence-supported options including cognitive behavioral therapy and selected prescription medicines. (The North American Menopause Society, 2023)
The review assessed supplements as a category, pooling products with different ingredients, doses and study designs. Its conclusion therefore sets the standard for every formulation: each one has to show its own data, in the women it is meant for.
The newest prescription options are the neurokinin receptor antagonists, fezolinetant and elinzanetant, which act on the brain pathway that triggers hot flashes. (Flanagan, 2026) They are medicines for bothersome symptoms, prescribed and monitored by a physician. A food supplement occupies a different place in care: it suits women who want a non-prescription option and, in the case described below, women whose symptoms come with metabolic changes.
Where a combined formulation can fit
Lo.Li. Pharma International has developed a formulation combining myo-inositol (2 g), soy isoflavones (80 mg, including 50 mg genistin) and cocoa polyphenols (30 mg) in a daily dose, for women in whom vasomotor symptoms coincide with metabolic changes after menopause.
Two clinical studies have evaluated this combination in postmenopausal women with metabolic syndrome. In a randomized, placebo-controlled study of 60 women, six months of supplementation was associated with lower fasting glucose and triglycerides than placebo; vasomotor symptoms were not assessed. (D’Anna et al., 2014)
A retrospective study of 200 women treated for six months reported fewer and less severe hot flashes and night sweats on a patient-reported questionnaire, with the proportion reporting moderate hot flashes falling from 59% to 27%. The study had no control group, so a placebo response cannot be excluded. (Mainini et al., 2024)
The combination has been studied in postmenopausal women with metabolic syndrome. A small randomized trial found lower fasting glucose and triglyceride levels than placebo at six months. A separate uncontrolled study reported improvements in self-reported vasomotor symptoms over the same period. A randomized, placebo-controlled trial with validated symptom measures is needed to establish whether the formulation reduces hot flashes and night sweats.
What distributors should examine before launch
Mordor Intelligence estimates the global phytoestrogen supplements market at USD 4.53 billion in 2025 and forecasts USD 5.78 billion by 2030. (Mordor Intelligence, 2025)
The report covers several applications, so these values should be presented as an adjacent category indicator, rather than the total market for non-hormonal treatment of hot flashes. Sales forecasts also provide no proof of clinical effectiveness. This distinction is commercially useful. It helps separate consumer interest from substantiated claims and prevents a market report from carrying a clinical argument it cannot support.
Product assessment should begin with the intended use and the evidence for the finished formulation. Useful questions include:
- Does the research involve women with the symptoms the product intends to address?
- Were the tested ingredients and doses equivalent to those in the commercial formulation?
- Which outcomes improved, and over what treatment period?
- Can the proposed claims be used under the destination market’s rules?
These questions help medical and commercial teams work from the same dossier. They also expose gaps early, before sales training or promotional materials turn a biological rationale into an unsupported promise.
The last question needs particular care in Europe. Health claims for botanical ingredients have been on hold at EU level since 2010, awaiting a decision by the European Commission, so what a plant-based product may say depends largely on national rules. Local regulatory advice should come before any communication plan.
Local access deserves equal attention. Pharmacy advice, specialist referrals and consumer expectations differ between countries. A distributor needs to identify where women seek help and what those channels require to recommend a product responsibly.
Lo.Li. Pharma International’s approach to clinical validation connects formulation evidence with registration, positioning and medical education.
Distributors who want to assess the formulation described above can request the clinical dossier, with both study reports, or book a call with our medical team to discuss the intended population and the claims permitted in their market, through our contact page: lolipharmainternational.com/contact-us.
Bibliography:
Flanagan MR. Paradigm shift in nonhormonal treatment options for vasomotor symptoms of menopause. Nurs Womens Health. 2026;30(3):248-253. https://doi.org/10.1016/j.nwh.2026.01.004
Khan SJ, Kapoor E, Faubion SS, et al. Vasomotor symptoms during menopause: a practical guide on current treatments and future perspectives. Int J Womens Health. 2023;15:273-287. https://doi.org/10.2147/IJWH.S365808
Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021;28(8):875-882. https://doi.org/10.1097/GME.0000000000001793
Koysombat K, McGown P, Nyunt S, et al. New advances in menopause symptom management. Best Pract Res Clin Endocrinol Metab. 2024;38(1):101774. https://doi.org/10.1016/j.beem.2023.101774
El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25):e506-e532. https://doi.org/10.1161/CIR.0000000000000912
Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med. 2008;168(14):1568-1575. https://doi.org/10.1001/archinte.168.14.1568
Yang L, Toriola AT. Menopausal hormone therapy use among postmenopausal women. JAMA Health Forum. 2024;5(9):e243128. https://doi.org/10.1001/jamahealthforum.2024.3128
The North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://doi.org/10.1097/GME.0000000000002028
Andrews R, Lacey A, Bache K, et al. Hormone replacement therapy uptake and discontinuation trends from 1996-2023: an observational study of the Welsh population. BJOG. 2025. https://doi.org/10.1111/1471-0528.18220
The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. https://doi.org/10.1097/GME.0000000000002200
D’Anna R, Santamaria A, Cannata ML, et al. Effects of a new flavonoid and myo-inositol supplement on some biomarkers of cardiovascular risk in postmenopausal women: a randomized trial. Int J Endocrinol. 2014;2014:653561. https://doi.org/10.1155/2014/653561
Mainini G, Ercolano S, De Simone R, et al. Dietary supplementation of myo-inositol, cocoa polyphenols, and soy isoflavones improves vasomotor symptoms and metabolic profile in menopausal women with metabolic syndrome: a retrospective clinical study. Medicina (Kaunas). 2024;60(4):598. https://doi.org/10.3390/medicina60040598
Mordor Intelligence. Phytoestrogen supplements market size and share: growth trends and forecasts (2025-2030). Market report. 2025. Accessed 14 October 2026. https://www.mordorintelligence.com/industry-reports/phytoestrogen-supplements-market

